Thermo Fisher Scientific Reports Full-Year 2022 Revenue of $44.92 Billion, Up 15% Year-Over-Year

 

"We have had another extraordinary year, surpassing our goals and delivering for all our stakeholders in 2022," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific Inc. "Thanks to our incredible global team, we successfully executed our proven growth strategy, effectively navigated the macro environment and delivered impressive financial results as we continued to help our customers make the world healthier, cleaner and safer."
 

　　The Fourth Quarter of 2022
 

According to the report, in the fourth quarter of 2022, Thermo Fisher Scientific's revenue was $11.45 billion, compared to $10.7 billion in 2021, representing a 7% increase. Organic revenue decreased by 3%, core organic revenue grew by 14%, and COVID-19 testing revenue was $370 million.
 

In the fourth quarter of 2022, GAAP operating income was $1.86 billion, diluted earnings per share were $4.01, and the operating profit margin was 16.3%, compared to 23.7% in the fourth quarter of 2021; Non-GAAP adjusted operating income in the fourth quarter of 2022 was $2.56 billion, earnings per share were $5.40, and the adjusted operating profit margin was 22.4%, compared to 29.5% in the fourth quarter of 2021.
 

　　Throughout 2022
 

In 2022, Thermo Fisher Scientific's total annual revenue was $44.92 billion, a year-on-year increase of 15%. Organic revenue saw slight growth, with core organic revenue growing by 14%, and COVID-19 testing revenue reaching $3.11 billion.
 

According to statistics, Thermo Fisher Scientific's full-year 2022 GAAP revenue was $8.39 billion, with diluted earnings per share of $17.63, and an operating profit margin of 18.7%, compared to 25.6% in 2021. The full-year Non-GAAP adjusted revenue was $10.99 billion, with adjusted earnings per share of $23.24, and an adjusted operating profit margin of 24.5%, compared to 31.0% in 2021.
 

　　Performance of Various Departments in 2022
 

According to the data, in 2022, Thermo Fisher Scientific's life sciences solutions revenue was $13.532 billion, accounting for 30.1%, with an operating profit margin of 41.2%; analytical instruments business revenue was $6.624 billion, accounting for 14.7%, with an operating profit margin of 22.8%; specialty diagnostics business revenue was $4.763 billion, accounting for 10.6%, with an operating profit margin of 21.5%; laboratory products and biopharmaceutical services revenue was $22.511 billion, accounting for 50.1%, with an operating profit margin of 12.8%.
 

　　Outlook for Fiscal Year 2023
 

Thermo Fisher Scientific Inc. will officially initiate its full-year 2023 revenue and adjusted EPS guidance. The company forecasts 2023 revenue to reach $45.3 billion, with core organic growth of 7% for the entire year. Adjusted earnings per share are expected to be $23.70.
 

　　About Thermo Fisher Scientific
 

Thermo Fisher Scientific serves the scientific community with a mission to help customers make the world healthier, cleaner, and safer. Whether it’s accelerating life science research, solving complex analytical challenges, enhancing laboratory productivity, improving patient health through diagnostics, or developing and manufacturing life-changing therapies, Thermo Fisher Scientific will support its customers every step of the way.